# Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

> **NCT04217421** · PHASE3 · RECRUITING · sponsor: **dr. M.J.N.L. Benders** · enrollment: 236 (estimated)

## Conditions studied

- Congenital Heart Disease in Children
- Neuroprotection

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Mannitol

## Key facts

- **NCT ID:** NCT04217421
- **Lead sponsor:** dr. M.J.N.L. Benders
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-14
- **Primary completion:** 2026-10-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04217421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04217421, "Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04217421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*